BioMarin Pharmaceutical/ US09061G1013 /
| 6/29/2022 9:59:55 PM | Chg. +0.66 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 83.89USD | +0.79% | 43,554 Turnover: 3.63 mill. |
-Bid Size: - | -Ask Size: - | 15.52 bill.USD | 0.00% | - |
Fundamentals
| FY 2021 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -0.35 USD | -107.37% |
| EPS Diluted: | -0.35 USD | - |
| Revenues per Share: | 10.04 USD | -1.94% |
| Book Value per Share: | 23.22 USD | 2.78% |
| Cash Flow per Share: | 1.66 USD | 252.35% |
| Dividend per Share: | 0.00 USD | - |
| Total | in mill. | |
| Revenues: | 1,846.30 USD | -0.76% |
| Net Income: | -64.10 USD | -107.46% |
| Operating Cash Flow: | 304.50 USD | - |
| Cash and Cash Equivalents: | 587.30 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 8.36 | 8.80 |
| P/BV ratio: | 3.61 | 3.80 |
| P/CF Ratio: | 50.69 | 53.36 |
| PEG: | 2.23 | - |
| Earnings Yield: | -0.42% | -0.40% |
| Dividend Yield: | 0.00% | 0.00% |
| Market Capitalization | ||
| Market Capitalization: | 15.52 bill. USD | 16.25 bill. USD |
| Free Float Market Cap.: | 9.14 bill. USD | 9.57 bill. USD |
| Market Cap. / Employee: | 5.07 mill. USD | 5.34 mill. USD |
| Shares Outstanding: | 185 mill. | |
Profitability
| Gross Profit Margin: | 100.00% |
| EBIT Margin: | -4.46% |
| Net Profit Margin: | -3.47% |
| Return on Equity: | -1.50% |
| Return on Assets: | -1.07% |
Financial Strength
| Liquidity I / Cash Ratio: | 108.80% |
| Liquidity II / Quick Ratio: | 108.80% |
| Liquidity III / Current Ratio: | 421.34% |
| Debt / Equity Ratio: | 40.57% |
| Dynam. Debt / Equity Ratio: | 569.00% |
Efficiency
| Employees: | 3,045 |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | 606,338.26 USD |
| Net Income / Employee: | -21,050.90 USD |
| Total Assets / Employee: | 1,971,527.09 USD |
| * Fiscal Year End: | 12/31/2021 |
| Accounting Standard: | US GAAP |
| Currency: | USD |